← XTL BIOPHARMACEUTICALS LTD XTLB
Market Price
$2.69
Market Cap
$6.61M
P/E Ratio
N/A
Revenue (FY 2025)
↓-100.0% YoY
$451.00K
Full year reported
Net Income
↓-578.6% YoY
-$6.97M
Net Margin: N/A
Free Cash Flow
N/A
FCF Yield: N/A
EPS (Diluted)
N/A
Basic: N/A
Return on Equity
Efficiency
N/A
ROA: -4,198.2%
⚡ N/A due to negative equity (share buybacks or other)
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (XTLB)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | — | — | — | $-2.5M | — | — | — | — | — | — |
| FY 2017 | — | — | — | $-0.8M | +69.3% | — | — | $-0.0M | $-0.0M | — |
| FY 2018 | — | — | — | $3.0M | +482.3% | — | — | $-0.1M | $-0.1M | -1,383.3% |
| FY 2019 | — | — | — | $-1.3M | -145.1% | — | — | $-0.1M | $-0.1M | -6.7% |
| FY 2020 | — | — | — | $-0.8M | +41.9% | — | — | $-0.0M | $-0.0M | +64.2% |
| FY 2021 | — | — | — | $0.4M | +155.6% | — | — | — | — | — |
| FY 2022 | — | — | — | $-1.3M | -409.9% | — | — | — | — | — |
| FY 2023 | $0.0M | — | $0.0M | $-1.8M | -32.2% | — | — | — | — | — |
| FY 2024 | $0.5M | +1,000.0% | $0.0M | $-1.0M | +42.4% | — | — | — | — | — |
| FY 2025 | — | -100.0% | — | $-7.0M | -578.6% | — | — | — | — | — |
Valuation
Market Price
$2.69
Market Cap
$6.61M
Enterprise Value
N/A
P/E Ratio
N/A
P/B Ratio
N/A
FCF Yield
N/A
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
Return on Equity (ROE)
N/A (Negative Equity)
Return on Assets (ROA)
-4,198.19%
Asset Turnover
2.72x
Revenue 3-Yr CAGR
N/A
Financial Health & Liquidity
Current Ratio
0.05
Cash Ratio
0.18
Debt / Equity
N/A
Debt / Assets
N/A
Cash & Equivalents
$76.00K
Total Debt
N/A
Book Value / Share
$-0.10
Cash Flow Efficiency
Operating Cash Flow
N/A
Capital Expenditures (CapEx)
$54.00K
Free Cash Flow
N/A
OCF / Revenue
N/A
FCF / Revenue
N/A
FCF 3-Yr CAGR
N/A
Per Share Metrics
EPS (Diluted)
N/A
EPS (Basic)
N/A
Dividends / Share
N/A
Book Value / Share
$-0.10
EPS YoY Growth
N/A
Balance Sheet (FY 2025)
Total Assets
$166.00K
Total Liabilities
$166.00K
Stockholders' Equity
-$254.00K
Current Assets
$22.00K
Current Liabilities
$420.00K